Genzyme board rejects Sanofi bid

Aug 30, 2010

The board of directors at US biotechnology firm Genzyme has unanimously rejected an 18.5-billion-dollar takeover offer from French pharmaceutical giant Sanofi-Aventis, Genzyme said Monday.

"The Genzyme board of directors met last (Sunday) night (and) unanimously affirmed its previous rejection of Sanofi's proposal," the company said in a statement.

A letter to Sanofi , signed by Genzyme chief executive Henri Termeer, recalled that the board had turned down an earlier offer on August 11.

The latest proposal, it said, "provides no new information and no improvement in price, and therefore fails to establish a basis for engagement by the Genzyme board."

It added that the board was "not prepared to engage in merger negotiations with Sanofi based upon an opportunistic proposal with an unrealistic starting price that dramatically undervalues our company."

Speaking during a telephone conference call, Sanofi chief executive Chris Viehbacher said Genzyme's response was "not surprising."

In an interview appearing Monday in the French financial newspaper Les Echos, Viehbacher said he was in no hurry to pursue a bid to acquire Genzyme.

"We want to show our determination and our seriousness, without appearing to be threatening right away," he told the paper.

"There is still lots of time."

Sanofi-Aventis unveiled its latest 18.5-billion-dollar (14.5-billion-euro) offer for Genzyme on Sunday, hinting it might launch a hostile bid.

Sanofi said it was disclosing to Genzyme's shareholders the contents of its offer, which it initially made in July, after the company's management rejected it on August 11 and declined to enter into talks.

Sanofi said it preferred to enter into constructive talks with Genzyme's management but failing that it was "prepared to consider all alternatives to successfully complete this transaction."

A Sanofi spokesman stressed that for the moment this "is not a hostile offer ... but a proposal addressed to Genzyme's management."

Explore further: Small doses of resistant starch encourage the growth of beneficial gut fauna

add to favorites email to friend print save as pdf

Related Stories

Sanofi to deliver swine flu vaccine in October

Sep 21, 2009

(AP) -- Sanofi-Aventis SA will begin delivering the first doses of its new swine flu vaccine in the United States by mid-October, the head of France's largest pharmaceutical company said Monday.

EMC raises offer for Data Domain

Jul 06, 2009

Computer storage giant EMC raised its offer to purchase data storage firm Data Domain on Monday in a bid to top a rival offer for the company by data management firm NetApp.

Recommended for you

Solving the Hox Specificity Paradox

Jan 22, 2015

The remarkable diversity of anatomical features along the body axis of animals—the differences between the head, the thorax and the abdomen, for example—is determined by proteins in the Hox family. But ...

The Facebook of plant science

Jan 21, 2015

By building PhotosynQ - a handheld device with sensors and an online data-sharing and analysis platform - a team of Michigan State University researchers is creating the plant-science equivalent of Facebook.

New computation method helps identify functional DNA

Jan 21, 2015

Striving to unravel and comprehend DNA's biological significance, Cornell scientists have created a new computational method that can identify positions in the human genome that play a role in the proper ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.